To Evaluate the Efficacy and Safety of Ipsilateral Supraclavicular Lymph Node Dissection for Breast Cancer Patients

Inclusion Criteria:

1. Female patients aged ≤ 80 years old.

2. ECOG score 0-1 points;

3. Breast cancer meets the following criteria: histologically diagnosed as invasivebreast cancer, known ER, PR, HER2, KI67 status, pathologically diagnosed asipsilateral supraclavicular lymph node metastasis (both cytology andhistopathology);

4. Estimated patient survival time exceeding three months;

5. No obvious contraindications for surgery or radiotherapy;

6. The researcher judged that they were able to comply with the research protocol.

7. Those who participate in other clinical trials (including intervention or nonintervention studies) at the same time and are judged by the researchers not toaffect the research protocol can be enrolled normally.

8. Voluntarily participate in this study and sign an informed consent form.

Exclusion Criteria:

1. Stage IV (metastatic) breast cancer;

2. Bilateral breast cancer;

3. Received radiotherapy and surgical treatment (excluding local puncture) foripsilateral supraclavicular metastatic lymph nodes before enrollment;

4. History of breast cancer or other malignant tumors, but excluding cured cervicalcarcinoma in situ, skin basal cell carcinoma or skin squamous cell carcinoma;

5. Individuals with severe primary diseases such as cardiovascular, cerebrovascular,liver, and kidney that are difficult to tolerate surgery or radiation therapy;

6. Having a history of immunodeficiency, including HIV testing positive, or havingother acquired or congenital immunodeficiency diseases, or having a history of organtransplantation;

7. Suffering from severe comorbidities or other comorbidities that may interfere withthe planned treatment, or any other circumstances in which the researcher deems thepatient unsuitable to participate in this study.